Impax Misled Investors About Manufacturing Issues, Suit Says

Law360, New York (April 9, 2013, 2:28 PM EDT) -- Impax Laboratories Inc. was hit with a proposed class action in California federal court Monday, accusing it of misleading investors about poor conditions at one of its manufacturing plants, delaying approval for two proposed drugs and causing its stock to trade at inflated prices.

According to pension fund Haverhill Retirement System, Impax and three of its current and former top executives had issued false and misleading public statements about deficiencies at its Hayward, Calif., manufacturing plant and how they would affect regulatory approval of its planned...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Haverhill Retirement System v. Impax Laboratories, Inc., et al


Case Number

3:13-cv-01566

Court

California Northern

Nature of Suit

Securities/Commodities

Judge

Edward M. Chen

Date Filed

April 8, 2013

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.